



Update 77 COVID-19 Coronavirus Disease 07th of July 2021





GLOBAL
↑
181 843 482
Confirmed cases
171 800 000 recovered
3 938 172 deaths

USA
(7-days incidence 26,5)
↑
33 499 531
confirmed cases
32 700 000 recovered
601 750 deaths

India
(7-days incidence 24,9)
↓
30 316 897
confirmed cases
28 970 000 recovered
397 637 deaths

Brazil
(7-days incidence 227,8)
↓
18 513 305
confirmed cases
16 840 000 recovered
515 985 deaths

- News:**
- The WHO has updated its [patient care guidelines to include interleukin-6 receptor blockers](#), a class of medicines that are lifesaving in patients who are severely or critically ill with COVID-19, especially when administered alongside corticosteroids.
 - COVAX: released a "[Joint COVAX Statement on the Equal Recognition of Vaccines](#)" on 1 July. All COVID-19 vaccines that have been deemed safe and effective by the World Health Organization and/or the 11 Stringent Regulatory Authorities (SRAs) should be taking in account when making decisions on who is able to travel or attend events. Any measure that only allows people protected by a subset of WHO-approved vaccines to benefit from the re-opening of travel into and with that region would effectively create a two-tier system, further widening the global vaccine divide and exacerbating the inequities we have already seen in the distribution of COVID-19 vaccines. It would negatively impact the growth of economies that are already suffering the most.
 - WHO: On the 30 June the Heads of the World Bank Group, International Monetary Fund, World Health Organization, and World Trade Organization today convened for the first meeting of the [Task Force on COVID-19 Vaccines, Therapeutics and Diagnostics for Developing Countries](#).
 - WHO/Europe: Launched a new [monitoring tool, tracking rates of COVID-19 in UEFA Euro 2020 host cities](#) at 30 June. The explorer provides: epidemiological trends across the Region, an event-based surveillance system, details of public health and social measures, and tracking of cases of COVID-19 in host countries.
 - FAA: Since the beginning of the year, 3100 cases of "Air Rage" have been counted. This refers to passengers who attack, threaten or insult cabin crew and fellow passengers. That was a multiple of the pre-corona numbers. In 2350 of these 3100 cases, they were mask refusers. On the occasion of the gradual normalisation of air traffic after more than a year of forced break, there are warnings of potential new dangers. According to an assessment, this includes pilots who have been out of practice and possible damage to the aircraft, such as nests in the engines, and also raging mask refusers on board.
 - CDC: Published a study on the "[Efficacy of Portable Air Cleaners and Masking for Reducing Indoor Exposure to Simulated Exhaled SARS-CoV-2 Aerosols — United States, 2021](#)".
 - CDC: Published an [overview of publications about COVID-19 for laboratories](#).
- Topics:**
- Global situation
 - European situation
 - Vaccination news
 - SARS-CoV-2 VOIs and VOCs
- Subject in Focus:** Vaccine research update
- Other Infectious Disease Outbreaks
 - NATO Member State:** Summary of information on the individual national Corona restrictions
 - Travel Recommendations and other Useful Links



Disclaimer:
This update provided by the NATO Centre of Excellence (NATO MILMED COE) on its website is for general information purposes only and cannot be considered as official recommendation. All national and international laws, regulations, and guidelines as well as military orders supersede this information.
All information is provided in good faith, however, the NATO MILMED COE makes no representation or warranty of any kind, express or implied, regarding the accuracy, adequacy, validity, reliability, availability or completeness of any information.
The information published on this website is not intended to substitute professional medical advice, diagnosis or treatment.
The NATO MILMED COE disclaim any liability in connection with the use of this information.

EUROPE
↑
53 509 619
confirmed cases
51 540 000 recovered
1 153 276 deaths

France
(7-days incidence 19,1)
↓
5 772 844
confirmed cases
5 624 000 recovered
111 057 deaths

Russia
(7-days incidence 95,5)
↑
5 428 961
confirmed cases
5 025 000 recovered
132 314 deaths

TUR
(7-days incidence 46,2)
↓
5 420 156
confirmed cases
5 282 000 recovered
49 687 deaths

Situation by WHO Region, as of 06th July

Global epidemiological situation overview; WHO as of 06 July 2021


Globally, after a decline in newly reported cases for seven consecutive weeks, there has been a slight increase in new weekly cases in the last two weeks, with over 2.6 million cases reported last week (28 June – 4 July 2021) as compared to the previous week (Figure 1). The number of weekly deaths continued to decrease, with just under 54 000 deaths reported in the past week, a 7% decrease as compared to the previous week. This is the lowest weekly mortality figure since early October 2020. The cumulative number of cases reported globally now exceeds 183 million and the number of deaths is almost 4 million.

This week, **all Regions** except the **Americas** reported an increase in new cases. The **European Region** reported a sharp increase in incidence (30%) whereas the **African region** reported a sharp increase in mortality (23%) as compared to the previous week. **All Regions**, with the exception of the **Americas and South-East Asia Regions**, reported an increase in the number of deaths in the past week.

In the past week, the five countries reporting the highest number of new cases were:

- **Brazil**; reporting 364 709 new cases; 30% decrease,
- **India**; reporting 312 250 new cases; 11% decrease,
- **Colombia**; reporting 204 556 new cases; 5% increase,
- **Indonesia**; reporting 168 780 new cases; 35% increase,
- **United Kingdom**; reporting 161 805 new cases; 67% increase


Figure 1. COVID-19 cases reported weekly by WHO Region, and global deaths, as of 4 July 2021**



Eastern Mediterranean Region

The Eastern Mediterranean Region reported over 245 000 new cases and over 3400 new deaths, an 11% and a 2% increase respectively as compared to the previous week. Following more than two months of decrease in weekly case incidence, for the third consecutive week the region showed an increase of case incidence, while mortality remained relatively stable for the past month. The highest numbers of new cases were reported from the Islamic Republic of Iran (83 054 new cases; 98.9 new cases per 100 000; a 17% increase), Iraq (43 979 new cases; 109.3 new cases per 100 000; a 16% increase), and Tunisia (35 452 new cases; 300.0 new cases per 100 000; a 59% increase).


The highest numbers of new deaths were reported from the Islamic Republic of Iran (916 new deaths; 1.1 new deaths per 100 000; a 7% increase), Tunisia (682 new deaths; 5.8 new deaths per 100 000; a 10% increase), and Afghanistan (549 new deaths; 1.4 new deaths per 100 000; a 4% increase).



European Region

The European Region reported over 505 000 new cases and over 6900 new deaths. Following almost three months of declining trends, the region showed for the second consecutive week an increase in the number of new weekly cases and deaths, a 30% and a 6% increase respectively as compared to the previous week. The highest numbers of new cases were reported from the United Kingdom (161 805 new cases; 238.3 new cases per 100 000; a 67% increase), the Russian Federation (159 650 new cases; 109.4 new cases per 100 000; a 19% increase), and Turkey (36 224 new cases; 43.0 new cases per 100 000; a 7% decrease).


The highest numbers of new deaths were reported from the Russian Federation (4643 new deaths; 3.2 new deaths per 100 000; an 18% increase), Turkey (350 new deaths; <1 new deaths per 100 000; a 13% decrease), and Germany (276 new deaths; <1 new deaths per 100 000; a 25% decrease).



South-East Asia Region

The South-East Asia Region reported just under 613 000 new cases and over 11 000 new deaths, a 7% increase and a 12% decrease respectively as compared to the previous week. Following a decreasing trend in weekly case incidence for almost two months, mostly driven by the decrease in cases reported in India, the region showed a slight increase of cases this week. Bangladesh, Indonesia, Myanmar and Thailand continue to report large increases in the number of newly reported cases and deaths for this week.

The highest numbers of new cases were reported from India (312 250 new cases; 22.6 new cases per 100 000; an 11% decrease), Indonesia (168 780 new cases; 61.7 new cases per 100 000; a 35% increase), and Bangladesh (56 511 new cases; 34.3 new cases per 100 000; a 54% increase). The highest numbers of new deaths were reported from India (6254 new deaths; 0.5 new deaths per 100 000; a 31% decrease), Indonesia (3444 new deaths; 1.3 new deaths per 100 000; a 39% increase), and Bangladesh (893 new deaths; 0.5 new deaths per 100 000; a 43% increase).




Updates from the European Region

Western Pacific Region

The Western Pacific Region reported over 128 000 new cases and over 1900 new deaths, a 10% and a 7% increase respectively. Cambodia, Fiji and Malaysia, continue to report increases in both weekly cases and deaths.

The highest numbers of new cases were reported from Malaysia (44 145 new cases; 136.4 new cases per 100 000; an 18% increase), the Philippines (38 507 new cases; 35.1 new cases per 100 000; similar to last week), and Mongolia (15 478 new cases; 472.1 new cases per 100 000; a 4% decrease).


The highest numbers of new deaths were reported from the Philippines (819 new deaths; <1 new deaths per 100 000; a 16% increase), Malaysia (550 new deaths; 1.7 new deaths per 100 000; a 3% increase), and Japan (185 new deaths; <1 new deaths per 100 000; a 28% decrease).



African Region

The African Region reported over 204 000 new cases and over 3300 new deaths, a 15% and a 23% increase respectively as compared to the previous week. For the sixth consecutive week, the region continues to show a marked increase in weekly case incidence and mortality; the Southern and Eastern parts of Africa remain the most affected areas on the continent. The highest numbers of new cases were reported from South Africa (132 450 new cases; 223.3 new cases per 100 000 population; a 28% increase), Zambia (16 456 new cases; 89.5 new cases per 100 000; a 14% decrease), and Namibia (9342 new cases; 367.7 new cases per 100 000; a 28% decrease).


The highest numbers of new deaths were reported from South Africa (1729 new deaths; 2.9 new deaths per 100 000 population; a 46% increase), Zambia (430 new deaths; 2.3 new deaths per 100 000; a 16% increase), and Uganda (325 new deaths; <1 new deaths per 100 000; a 34% increase).



Region of the Americas

The Region of the Americas reported over 992 000 new cases and over 26 000 new deaths, a 13% and an 11% decrease respectively compared to the previous week. The Americas is the only region showing a decrease in both weekly case incidence and mortality. For the first time since October 2020, the region reported under 1 million weekly cases. However, several countries from South America, Central America and the Caribbean are still reporting high case incidence and mortality over the past weeks. The highest numbers of new cases were reported from Brazil (364 709 new cases; 171.6 new cases per 100 000; a 30% decrease), Colombia (204 556 new cases; 402.0 new cases per 100 000; similar to the previous week), and Argentina (137 852 new cases; 305.0 new cases per 100 000; a 5% increase).

The highest numbers of new deaths were reported from Brazil (10 810 new deaths; 5.1 new deaths per 100 000; a 14% decrease), Colombia (4402 new deaths; 8.7 new deaths per 100 000; a 4% decrease), and Argentina (3403 new deaths; 7.5 new deaths per 100 000; a 9% decrease).



Global Situation



RUS: As of July 7, the seven-day rolling average number of daily new cases stands at 22,926, representing a two-fold increase compared to one month ago. The capital city of Moscow and its outlying region as well as the city of St. Petersburg accounted for approximately 50% of new cases. On July 1, Russia reported 697 COVID-19 related deaths, representing a record-high number since the beginning of the pandemic. As of June 18, 90% of all sequenced cases are attributable to the Delta variant. On June 29, Russian officials also confirmed the first Delta Plus variant (B.1.617.2.1 or AY.1) case within its borders days after media sounded the alarm about the presence of the potentially more dangerous new strain.

ARG: Since April, the country experienced a rise in the seven-day rolling average of daily new cases from 12,162 on April 1 to an all-time high of 33,171 on May 23. Since then, cases started to decline to an average 18,005 on June 22 and recently increased again to 19,047 on July 3. The 14-day test positivity rate has remained extremely high over past months with numbers that have oscillated between 65% and an all-time high of 79% since June. Since June 20, five cases have been attributed to the Delta variant. So far, all of the cases have been travellers with the two most recent cases arriving from the United States and Venezuela. According to the Ministry of Health (MOH), during 2020, there was an excess in mortality rate from all causes of 10.6%. Officials have attributed this increase to the pandemic.

UGA: As of July 1, 762 deaths were added to the country's cumulative total. The adjustment came following the addition of probable COVID-19 deaths that were observed among unconfirmed cases. Officials have stated, that moving forward, all deaths will be reported in real-time as either PCR confirmed or probable COVID-19 deaths.

ZAF: South Africa is in its third wave, with a seven-day rolling average number of daily new cases increasing from 4,042 on June 1 to 15,500 on July 7. The 14-day test positivity rate has also escalated from 10.3% on June 1 to 25.4% on July 4, with the 14-day testing rate per 100,000 individuals also increasing from 855 to 1,127 tests, respectively. This suggests that the epidemic is growing and that there is still a substantial degree of community transmission where mild or asymptomatic cases are not being detected.

JAP/IOC: The Olympic opening ceremony is scheduled to take place with a reduced number of VIP guests. Japan's government plans to greatly reduce the originally planned 10,000 guests at the opening of the Games due to the coronavirus pandemic. The organizers have already banned spectators from abroad and set a cap on domestic spectators at the competitions.

Due to the current rising number of infections, Japan's Olympic organizers have called on citizens not to watch the marathon and walker competitions at the Olympic Games from the side of the road. On the same day, the Tokyo City Council announced that the torch relay starting on Friday in the Olympic City will be banned from public streets until the start of the Games. Tokyo reported 593 new infections within 24 hours, which means that the number of daily infections for 17 days in a row is now above the value of the same day of the previous week. The renewed rise in infections is fuelling the worries of many Japanese that the Olympics will become a super spreader event. On Wednesday, new coronavirus infections in Tokyo rose to their highest level in nearly two months.

IND: On Tuesday, the number of new coronavirus infections recorded within one day fell to its lowest level in more than three months. With 34,703 new cases, the authorities reported around 2860 fewer than in the previous week.

ESP: The number of new coronavirus infections has skyrocketed in recent days, especially among young people, with an incidence of almost 600. The nationwide incidence was 204 per 100,000 inhabitants in the past 14 days. On Friday, it had been 152.8.

GBR: From 19 July, all corona measures are to be terminated, thus eliminating distance rules, the home office regulation and the mask requirement as well as a limit on spectators at major events. However, the binding decision will only be taken after a further review of the pandemic data on 12 July.

IDN: In parts of Indonesia, medical oxygen is scarce because of the large number of corona patients in the hospitals. According to the competent authority, the demand is currently three to four times higher than normal, which is why there have been problems with the allocation. As of Saturday, at least 63 corona patients have died during treatment at a Yogyakarta city hospital - 33 of them during a temporary failure of the central supply of liquid oxygen. Meanwhile, the lockdown has been extended to the entire country. The nationwide coronavirus restrictions imposed on Wednesday will initially apply until July 20.

UEFA European Football Championship 2021 Surveillance by ECDC (week 27 June to 03 July)

From 24 June to 1 July 2021, following signals were detected with a potential public health impact to UEFA EURO 2020's host and participating countries:

According to multiple sources, from the beginning of UEFA EURO 2020 and as of 1 July 2021, seven countries have reported 2 472 SARS-CoV-2 positive cases linked to attendance at the championship's matches: **Denmark** (source 1, source 2) (35, of these five with Delta variant), **Finland** (436), **France** (3), **Sweden** (2), **Scotland** (1991), while fewer than five cases were reported by **Croatia** and the **Netherlands**.

According to the media and [WHO EURO 2020 explorer](#), among the [EURO 2020 host countries](#), an **increase of SARS-CoV-2 cases** was recently reported in St. Peterburg, **Russia**; Baku, **Azerbaijan**; Copenhagen, **Denmark**; and in Glasgow and London, **United Kingdom** (UK).

According to the media, SARS-CoV-2-related **hospitalisations** have increased in **St. Petersburg** in recent days.

The **majority** of new cases of SARS-CoV-2 in the **UK** are the **Delta variant**. According to [Public Health England](#), weekly SARS-CoV-2 variant cases data show as of 23 June 2021 that numbers of the Delta variant in the UK have risen by 35204 since last week to a total of 111157. The UK is reporting an increase in the notification rate, but hospitalisations remain stable.

Finland reported an increase of COVID-19 cases linked to UEFA EURO 2020 spectators.

In addition, **Russia** reported the first case of the Delta + K417N variant (currently classified as variant under investigation), according to a media report on 29 June 2021.

According to the media, in the monitoring period SARS-CoV-2 infection was detected in several players of the following national teams: **Croatia**.


ECDC assessment

In the countries where mass gathering events such as UEFA EURO 2020 take place, in the absence of sufficient mitigation measures the risk of local and pan-European transmission **risk of COVID-19**, including the spread of variants of concern, is expected to **increase**.

The risk of becoming infected with **other communicable diseases** in countries hosting UEFA EURO 2020 varies, but is **considered low** if preventive measures are applied, e.g. being fully vaccinated according to the national immunisation schedule, following hand and food hygiene, respiratory etiquette, refraining from any activities and contacts if any symptoms occur, and seeking prompt testing and medical advice as needed.

European Situation

Maps in support of the Council Recommendation on a coordinated approach to the restriction of free movement in response to the COVID-19 pandemic in the EU, as of 02 July 2021



ECDC COVID-19 surveillance report Week 25, as of 02 July 2021

Weekly surveillance summary

Overall situation

Due to technical issues impacting the ECDC database, data for week 25, 2021 are incomplete for Austria, Croatia, Cyprus, Norway and Sweden.

By the end of week 25 (week ending Sunday 27 June 2021), four countries in the European Union/European Economic Area (EU/EEA) had reported increasing case notification rates. Case rates in older age groups increased in one country and no countries reported increasing death rates. Absolute values of several other indicators, including hospital and ICU occupancy, remained high in some countries, but trends for these indicators were decreasing or stable. The median cumulative uptake of at least one vaccine dose among adults aged 18 years is 62% and above in the EU/EEA and 39% for full vaccination, as reported in the [COVID-19 Vaccine rollout overview](#).

Trends in reported cases and testing

- By the end of week 25, the 14-day case notification rate for the EU/EEA, based on data collected by ECDC from official national sources in 30 countries, was 39.0 (country range: 5-160) per 100 000 population. The rate has been decreasing for 12 weeks.
- Among the five countries with high case notification rates (at least 60 per 100 000 population), increases were observed in two countries (Cyprus and Portugal). Stable or decreasing trends in case rates of 1-7 weeks' duration were observed in three countries (Ireland, Latvia and Spain).
- Based on data reported to The European Surveillance System (TESSy) from 29 countries for people over 65 years old, high levels (at least 60 per 100 000 population) or increases in the 14-day COVID-19 case notification rates compared with last week were observed in one country (Portugal).
- Notification rates are dependent on several factors, one of which is the testing rate. Weekly testing rates for week 25, available for 29 countries, varied from 594 to 61 252 tests per 100 000 population. Austria had the highest testing rate, followed by Denmark, Cyprus, Greece and Slovenia.
- Among the one country in which weekly test positivity was high (at least 3%), one country (Spain) had observed an increase in test positivity compared with the previous week.

Hospitalisation and ICU

- Pooled data from 25 countries for week 25 showed that there were 6 patients per 100 000 population in hospital due to COVID-19. According to pooled weekly hospital admissions data from 18 countries, new admissions were 1 per 100 000 population.
- Pooled data from 19 countries for week 25 showed that there was 1 patient per 100 000 population in ICU due to COVID-19. Pooled weekly ICU admissions based on data from 11 countries showed that there were 0 new admissions per 100 000 population.
- Hospital and/or ICU occupancy and/or new admissions due to COVID-19 were high (at least 25% of the peak level during the pandemic) or had increased compared with the previous week in six countries (Bulgaria, Cyprus, France, Latvia, Lithuania and Portugal). However, in 13 countries, there were decreases in these indicators compared with the previous week.

Mortality


- The 14-day COVID-19 death rate for the EU/EEA, based on data collected by ECDC from official national sources for 30 countries, was 11.3 (country range: 0.0-75.0) per million population. The rate has been decreasing for nine weeks.
- Among the 10 countries with high 14-day COVID-19 death rates (at least 10 per million), none had increasing trends. Stable or decreasing trends in death rates of 1-11 weeks' duration were observed in 10 countries (Bulgaria, Croatia, Germany, Greece, Latvia, Lithuania, Poland, Romania, Slovakia and Slovenia).

Variants of concern (VOC) and variants of interest (VOI)

- Sequencing capacity varies greatly across the EU/EEA; 14 EU/EEA countries (Belgium, Denmark, Estonia, France, Germany, Hungary, Iceland, Latvia, Lithuania, Luxembourg, Malta, Norway, Poland, and Romania) met the recommended level of 10% or 500 sequences of SARS-CoV-2-positive samples sequenced and reported to the [GISAID EpicCoV database](#) by 30 June 2021, or to TESSy by 27 June 2021 (data referring to the period 7 June to 20 June 2021). During the same period, eight countries sequenced and reported between 60 and 499 samples, six countries sequenced and reported 1-59 samples and two did not report data.
- Among the 14 countries with the recommended level of 10% or 500 sequences reported per week in the period from 7 June to 20 June 2021, 13 had a valid denominator. The median (range) of the VOC reported in all samples sequenced in the period in these 13 countries was 69.5% (40.6-96.7%) for B.1.1.7 (Alpha), 5.2% (0.0-40.4%) for B.1.617.2 (Delta), 1.0% (0.0-50.0%) for P.1 (Gamma), 0.1% (0.0-8.7%) for B.1.351 (Beta), 0.0% (0.0-9.6%) for B.1.617 and 0.0% (0.0-1.6%) for B.1.1.7+E484K.
- The median (range) of the VOI reported in all samples sequenced in the period for these 13 countries was 0.0% (0.0-1.4%) for B.1.620, 0.0% (0.0-0.7%) for B.1.525 (Eta), 0.0% (0.0-0.7%) for B.1.617.1 (Kappa) and 0.0% (0.0-0.1%) for B.1.621. A list of current variants of concern and variants of interest for the EU/EEA is published on [ECDC's website](#).

Long-term care facilities (LTCFs)

- Based on data reported to TESSy from four countries (Austria, France, the Netherlands and Slovenia), in week 25, the pooled incidence of COVID-19 cases among LTCF residents was 17.8 per 100 000 LTCF beds, the pooled incidence of fatal COVID-19 cases was 0.5 per 100 000 LTCF beds, and 1.8% of participating LTCFs reported one or more new COVID-19 cases among their residents.



Vaccination news

As of July 1, a total of 10 countries accounted for 76% of all vaccinations administered globally. The top five countries/territories with the highest number of cumulative people vaccinated with at least one dose per 100,000 population are Gibraltar (116,460), Malta (81,340), Palau (79,180), Iceland (76,010), and Falkland Islands (75,570).

EU: Europe's race to catch up on vaccinations against COVID-19 is progressing. In mid-April, the EU was still 25 percentage points behind the USA in terms of the number of adults with at least one vaccination. Currently, the gap is only 5 percentage points, and the gap continues to close. Meanwhile, nearly 40 million additional doses have been ordered from vaccine manufacturer Johnson & Johnson. Internal sources said that the additional doses would likely be delivered to other countries outside the EU.

BioNTech/ISR: According to the latest findings, the effectiveness of the BioNTech vaccination against the coronavirus has decreased significantly in recent weeks, according to the Ministry of Health. At the same time, the more aggressive Delta variant has spread throughout the country. Since June 6, the effectiveness of vaccination in preventing infection in Israel has fallen to 64 percent. This is also the case in the prevention of a disease with symptoms. However, 93 percent of the vaccination warded off a serious illness and hospitalization.

USA: President Joe Biden's vaccination target of vaccinating 70 percent of all adults at least once by July 4 was missed. So far, only 67 percent - or 173 million people - have received at least the first vaccination, data from the CDC shows. A good 58 percent of all adults are already fully vaccinated. The White House had already admitted at the end of June that the vaccination target could probably not be achieved on US Independence Day. The US seems to have reached a plateau beyond which there is little progress. On average, about one million people are vaccinated per day - significantly less than the more than three million people at the peak of the vaccination campaign in the spring.

KOR: The country plans to produce up to one billion mRNA vaccine doses. According to the Minister of Health, this is in talks with manufacturers such as Pfizer or Moderna. The cooperation could help alleviate the shortage of vaccines in Asia. How far the talks have progressed is initially unclear. Pfizer says no announcements are currently planned. BioNTech declined to comment. Moderna and CureVac were initially unable to comment.

ISR: In order to promote the vaccination campaign among young people, the Israeli rescue service is now also vaccinated in schools. All 12- to 18-year-olds accompanied by their parents can be vaccinated. So far, according to the Ministry of Health, around 36 percent of 10- to 19-year-olds have received a vaccination with the BioNTech/Pfizer vaccine, and around 24 percent have already received the second. Currently, despite a high vaccination rate, the number of registered new coronavirus infections has been rising significantly for a good two weeks.

Since around 700,000 doses of BioNTech's vaccine will expire by the end of July, they should be exchanged with South Korea. South Korea, in turn, will send the same number of one shipment to Israel in September and October.

ZAF: As of July 4, of the country's 58.5 million population, 3,155,717 individuals (5.4%) are vaccinated with at least one dose of a COVID-19 vaccine, while 479,772 individuals (0.8%) are fully vaccinated. Previously, the country terminated the use of the AstraZeneca vaccine due to poor effectiveness against the endemic Beta variant (B.1.351), in addition to halting the administration of the Johnson & Johnson vaccine due to safety concerns. To date, the use of both of these vaccines remains halted. By the end of June, of the roughly three million doses administered, about 480,000 were from Johnson & Johnson and the remaining 2.2 million from Pfizer.

RUS: As of July 4, 16% of Russia's 144 million population have received at least one dose of the Sputnik V vaccine or the EpiVacCorona vaccine. On June 22, Moscow ordered compulsory vaccination for 60% of service workers and will start offering booster doses of the Sputnik V vaccine for individuals who were vaccinated more than six months ago. Russia no longer expects to meet its goal of vaccinating 60% of its population by Fall 2021.

DEU: Despite the demands from politicians for a general corona vaccine recommendation for children and adolescents from the age of 12, the Standing Committee on Vaccination (STIKO) remains on its cautious course and continues to recommend vaccinations only for 12- to 17-year-olds with certain pre-existing conditions such as obesity, diabetes and chronic lung diseases.

ARG: According to the MOH data, as of July 4, of the country's 44.9 million population, 18,011,944 individuals (40.11%) are vaccinated with at least one dose of a COVID-19 vaccine, while 4,432,185 individuals (9.8%) are fully vaccinated. Argentina will continue to receive shipments of the Sputnik V vaccine, the Sinopharm vaccine, and the Oxford/AstraZeneca vaccine in the upcoming months.


USA: The U.S. government will send 1.5 million Moderna vaccine doses to Guatemala and two million to Vietnam. U.S. President Joe Biden has pledged to share 80 million U.S.-produced vaccines with countries around the world.

Share of people vaccinated against COVID-19, Jul 6, 2021

This data is only available for countries which report the breakdown of doses administered by first and second doses.

Our World in Data

+ Add country



Source: Official data collated by Our World in Data

CC BY

European Situation on Vaccination

Source: <https://gap.ecdc.europa.eu/public/extensions/COVID-19/vaccine-tracker.html#uptake-tab>

Total doses distributed to EU/EEA countries


456,759,796

380,303,844

Select View : Uptake full vaccination

Select Country : All EU/EEA countries

Cumulative uptake (%) of full vaccination among adults (18+) in EU/EEA countries as of 2021-07-07




Uptake full vaccination (%)




Cumulative uptake (%) of at least one vaccine dose and full vaccination among adults (18+) in EU/EEA countries as of 2021-07-07

by reporting week (data for the current week are preliminary)



Cumulative number of doses administered to adults (18+) in EU/EEA countries as of 2021-07-07

by reporting week (data for current week are preliminary)



Cumulative uptake (%) of full vaccination by age group in EU/EEA countries as of 2021-07-06

Country	80+ years	70-79 years	60-69 years	50-59 years	25-49 years
Austria	91.4%	70.8%	65.1%	48.6%	29.4%
Belgium	85.0%	75.1%	68.5%	46.1%	25.6%
Bulgaria	14.9%	23.4%	21.6%	16.9%	10.7%
Croatia	48.7%	60.6%	49.4%	33.7%	19.6%
Cyprus	85.2%	84.6%	67.0%	58.1%	39.3%
Czechia	75.0%	75.0%	58.9%	49.5%	17.7%
Denmark	100.0%	98.1%	87.3%	42.6%	13.0%
Estonia	60.3%	67.9%	57.1%	49.5%	28.3%
Finland	87.3%	69.3%	22.9%	12.4%	6.0%
France	69.6%	76.1%	55.4%	37.3%	17.7%
Germany	-	-	-	-	-
Greece	66.6%	74.5%	66.8%	53.0%	22.4%
Hungary	71.0%	82.7%	72.4%	63.3%	50.8%
Iceland	99.3%	100.0%	89.5%	79.7%	71.0%
Ireland	98.6%	97.4%	64.2%	83.8%	28.5%
Italy	88.1%	57.8%	48.6%	38.8%	18.5%
Latvia	30.9%	41.0%	35.8%	31.4%	29.7%
Liechtenstein	-	-	-	-	-
Lithuania	47.4%	64.7%	58.7%	44.7%	37.9%
Luxembourg	78.3%	79.0%	76.7%	70.7%	17.7%
Malta	92.4%	99.8%	97.0%	71.8%	58.6%
Netherlands	-	-	-	-	-
Norway	89.8%	95.3%	64.1%	25.7%	10.7%
Poland	59.3%	77.0%	60.1%	47.8%	33.8%
Portugal	96.6%	76.5%	68.1%	54.9%	16.1%
Romania	18.1%	34.0%	35.5%	32.9%	25.7%
Slovakia	47.3%	64.4%	55.2%	40.5%	26.8%
Slovenia	61.1%	68.8%	54.6%	41.3%	21.7%

Weekly doses

Cumulative doses

Variants Of Concern (VOC) Notable Update – Lambda variant Spotlight



Notable Update - Variants of Interest

Presently, the WHO continues to monitor variants of interest (VOI). These are defined as SARS-CoV-2 variants with genome mutations that could be associated with changes in epidemiology, antigenicity, or virulence, or can potentially have an impact on available diagnostics, vaccines, therapeutics, or public health measures. The following table summarizes the VOIs according to PANGO lineage or scientific name, the WHO re-labeling nomenclature, the country first identified, and some of the attributes that conferred the designation while further investigations are undergoing.

Lambda Variant (C.37)

There are concerns that the Lambda variant (C.37) could be upgraded to be deemed a VOC. Since February 2021, the Lambda variant has been found in at least 30 countries, with high rates of transmissibility. Recent upward trends observed, along with critical health care system situations and recent reports of increased deaths in Chile, Peru, Ecuador, and Argentina, are being likely associated with the rising prevalence of the Lambda variant.

Recent sequencing samples in **Peru** have reported that 81% of COVID-19 cases since April 2021 have been confirmed as the Lambda variant.

Similarly, **Argentina** reported an increase in the prevalence of the Lambda variant since the third week of February 2021, and between April 2 and May 19, 2021, the variant represented 37% of all sequenced COVID-19 cases.

In **Chile**, the prevalence of Lambda has increased over time, representing 32% of the sequenced cases reported in the last 60 days.

Summary

As of 6 July 2021, **2,212** sequences in the C.37 lineage have been detected since the lineage was identified:

location ↗	C.37 found		when found**	
	total	cumulative prevalence*	first	last
Peru	242	41%	30 Nov 2020	30 May 2021
Worldwide	2,212	< 0.5%	8 Nov 2020	23 Jun 2021

view changes over time change locations

* Apparent cumulative prevalence is the ratio of the sequences containing C.37 to all sequences collected since the identification of C.37 in that location. ** Dates are based on the sample collection date

! Read about biases

The strain has been detected in at least **32 countries** and **42 U.S. states**.

Source: <https://outbreak.info/situation-reports>
<https://bluedot.global/>

C.37

WHO: Lambda
 Nextstrain: 20D
 GISAID: GR/501Y.V1

VOC	VOI	VUM
VOC	VOI	VUM
15 Jun 2021	25 Jun 2021	14 Jun 2021
		18 Jun 2021

Peru 2,212

GR76V T76I DEL477P58 LAS20 A380S DR46G T859N

Explore all genes

Alpha Variant (B.1.1.7)

As of June 29, 151 countries have reported the Alpha (B.1.1.7) variant. Of those countries, 30% (n=45) are within Europe, 23% (n=35) within Asia, 20% (n=30) within Africa, 19% (n=28) within North and Central America, 6% (n=9) within South America, and 3% (n=4) within Oceania. Globally, of the 39,023 B.1.1.7 cases reported over the past seven days, 77% were reported in Europe, and 22% in North and Central America.

B.1.1.7

WHO: Alpha
 PHE: VOC-20DEC-01, VOC-202102/01
 Nextstrain: 20I/501Y.V1, 20B/501Y.V1
 GISAID: GRV, GR/501Y.V1
 related: B.1.1.7 + E484K

VOC	VOI	VUM
VOC	VOI	VUM
1 Feb 2021	report	29 Dec 2020
		18 Dec 2020
		18 Dec 2020

United Kingdom 963,023

DEL677P DEL644K N501Y DEL678P DEL679P DEL680K DEL681G DEL682I DEL683L DEL684E DEL685R DEL686L DEL687I DEL688R DEL689A DEL690A DEL691S DEL692E DEL693G DEL694S DEL695I DEL696V DEL697F DEL698L DEL699S DEL700A DEL701V DEL702I DEL703R DEL704K DEL705R DEL706L DEL707I DEL708R DEL709K DEL710R DEL711G DEL712S DEL713L DEL714I DEL715V DEL716I DEL717V DEL718I DEL719I DEL720V DEL721I DEL722I DEL723I DEL724I DEL725I DEL726I DEL727I DEL728I DEL729I DEL730I DEL731I DEL732I DEL733I DEL734I DEL735I DEL736I DEL737I DEL738I DEL739I DEL740I DEL741I DEL742I DEL743I DEL744I DEL745I DEL746I DEL747I DEL748I DEL749I DEL750I DEL751I DEL752I DEL753I DEL754I DEL755I DEL756I DEL757I DEL758I DEL759I DEL760I DEL761I DEL762I DEL763I DEL764I DEL765I DEL766I DEL767I DEL768I DEL769I DEL770I DEL771I DEL772I DEL773I DEL774I DEL775I DEL776I DEL777I DEL778I DEL779I DEL780I DEL781I DEL782I DEL783I DEL784I DEL785I DEL786I DEL787I DEL788I DEL789I DEL790I DEL791I DEL792I DEL793I DEL794I DEL795I DEL796I DEL797I DEL798I DEL799I DEL800I DEL801I DEL802I DEL803I DEL804I DEL805I DEL806I DEL807I DEL808I DEL809I DEL810I DEL811I DEL812I DEL813I DEL814I DEL815I DEL816I DEL817I DEL818I DEL819I DEL820I DEL821I DEL822I DEL823I DEL824I DEL825I DEL826I DEL827I DEL828I DEL829I DEL830I DEL831I DEL832I DEL833I DEL834I DEL835I DEL836I DEL837I DEL838I DEL839I DEL840I DEL841I DEL842I DEL843I DEL844I DEL845I DEL846I DEL847I DEL848I DEL849I DEL850I DEL851I DEL852I DEL853I DEL854I DEL855I DEL856I DEL857I DEL858I DEL859I DEL860I DEL861I DEL862I DEL863I DEL864I DEL865I DEL866I DEL867I DEL868I DEL869I DEL870I DEL871I DEL872I DEL873I DEL874I DEL875I DEL876I DEL877I DEL878I DEL879I DEL880I DEL881I DEL882I DEL883I DEL884I DEL885I DEL886I DEL887I DEL888I DEL889I DEL890I DEL891I DEL892I DEL893I DEL894I DEL895I DEL896I DEL897I DEL898I DEL899I DEL900I DEL901I DEL902I DEL903I DEL904I DEL905I DEL906I DEL907I DEL908I DEL909I DEL910I DEL911I DEL912I DEL913I DEL914I DEL915I DEL916I DEL917I DEL918I DEL919I DEL920I DEL921I DEL922I DEL923I DEL924I DEL925I DEL926I DEL927I DEL928I DEL929I DEL930I DEL931I DEL932I DEL933I DEL934I DEL935I DEL936I DEL937I DEL938I DEL939I DEL940I DEL941I DEL942I DEL943I DEL944I DEL945I DEL946I DEL947I DEL948I DEL949I DEL950I DEL951I DEL952I DEL953I DEL954I DEL955I DEL956I DEL957I DEL958I DEL959I DEL960I DEL961I DEL962I DEL963I DEL964I DEL965I DEL966I DEL967I DEL968I DEL969I DEL970I DEL971I DEL972I DEL973I DEL974I DEL975I DEL976I DEL977I DEL978I DEL979I DEL980I DEL981I DEL982I DEL983I DEL984I DEL985I DEL986I DEL987I DEL988I DEL989I DEL990I DEL991I DEL992I DEL993I DEL994I DEL995I DEL996I DEL997I DEL998I DEL999I DEL1000I DEL1001I DEL1002I DEL1003I DEL1004I DEL1005I DEL1006I DEL1007I DEL1008I DEL1009I DEL1010I DEL1011I DEL1012I DEL1013I DEL1014I DEL1015I DEL1016I DEL1017I DEL1018I DEL1019I DEL1020I DEL1021I DEL1022I DEL1023I DEL1024I DEL1025I DEL1026I DEL1027I DEL1028I DEL1029I DEL1030I DEL1031I DEL1032I DEL1033I DEL1034I DEL1035I DEL1036I DEL1037I DEL1038I DEL1039I DEL1040I DEL1041I DEL1042I DEL1043I DEL1044I DEL1045I DEL1046I DEL1047I DEL1048I DEL1049I DEL1050I DEL1051I DEL1052I DEL1053I DEL1054I DEL1055I DEL1056I DEL1057I DEL1058I DEL1059I DEL1060I DEL1061I DEL1062I DEL1063I DEL1064I DEL1065I DEL1066I DEL1067I DEL1068I DEL1069I DEL1070I DEL1071I DEL1072I DEL1073I DEL1074I DEL1075I DEL1076I DEL1077I DEL1078I DEL1079I DEL1080I DEL1081I DEL1082I DEL1083I DEL1084I DEL1085I DEL1086I DEL1087I DEL1088I DEL1089I DEL1090I DEL1091I DEL1092I DEL1093I DEL1094I DEL1095I DEL1096I DEL1097I DEL1098I DEL1099I DEL1100I DEL1101I DEL1102I DEL1103I DEL1104I DEL1105I DEL1106I DEL1107I DEL1108I DEL1109I DEL1110I DEL1111I DEL1112I DEL1113I DEL1114I DEL1115I DEL1116I DEL1117I DEL1118I DEL1119I DEL1120I DEL1121I DEL1122I DEL1123I DEL1124I DEL1125I DEL1126I DEL1127I DEL1128I DEL1129I DEL1130I DEL1131I DEL1132I DEL1133I DEL1134I DEL1135I DEL1136I DEL1137I DEL1138I DEL1139I DEL1140I DEL1141I DEL1142I DEL1143I DEL1144I DEL1145I DEL1146I DEL1147I DEL1148I DEL1149I DEL1150I DEL1151I DEL1152I DEL1153I DEL1154I DEL1155I DEL1156I DEL1157I DEL1158I DEL1159I DEL1160I DEL1161I DEL1162I DEL1163I DEL1164I DEL1165I DEL1166I DEL1167I DEL1168I DEL1169I DEL1170I DEL1171I DEL1172I DEL1173I DEL1174I DEL1175I DEL1176I DEL1177I DEL1178I DEL1179I DEL1180I DEL1181I DEL1182I DEL1183I DEL1184I DEL1185I DEL1186I DEL1187I DEL1188I DEL1189I DEL1190I DEL1191I DEL1192I DEL1193I DEL1194I DEL1195I DEL1196I DEL1197I DEL1198I DEL1199I DEL1200I DEL1201I DEL1202I DEL1203I DEL1204I DEL1205I DEL1206I DEL1207I DEL1208I DEL1209I DEL1210I DEL1211I DEL1212I DEL1213I DEL1214I DEL1215I DEL1216I DEL1217I DEL1218I DEL1219I DEL1220I DEL1221I DEL1222I DEL1223I DEL1224I DEL1225I DEL1226I DEL1227I DEL1228I DEL1229I DEL1230I DEL1231I DEL1232I DEL1233I DEL1234I DEL1235I DEL1236I DEL1237I DEL1238I DEL1239I DEL1240I DEL1241I DEL1242I DEL1243I DEL1244I DEL1245I DEL1246I DEL1247I DEL1248I DEL1249I DEL1250I DEL1251I DEL1252I DEL1253I DEL1254I DEL1255I DEL1256I DEL1257I DEL1258I DEL1259I DEL1260I DEL1261I DEL1262I DEL1263I DEL1264I DEL1265I DEL1266I DEL1267I DEL1268I DEL1269I DEL1270I DEL1271I DEL1272I DEL1273I DEL1274I DEL1275I DEL1276I DEL1277I DEL1278I DEL1279I DEL1280I DEL1281I DEL1282I DEL1283I DEL1284I DEL1285I DEL1286I DEL1287I DEL1288I DEL1289I DEL1290I DEL1291I DEL1292I DEL1293I DEL1294I DEL1295I DEL1296I DEL1297I DEL1298I DEL1299I DEL1300I DEL1301I DEL1302I DEL1303I DEL1304I DEL1305I DEL1306I DEL1307I DEL1308I DEL1309I DEL1310I DEL1311I DEL1312I DEL1313I DEL1314I DEL1315I DEL1316I DEL1317I DEL1318I DEL1319I DEL1320I DEL1321I DEL1322I DEL1323I DEL1324I DEL1325I DEL1326I DEL1327I DEL1328I DEL1329I DEL1330I DEL1331I DEL1332I DEL1333I DEL1334I DEL1335I DEL1336I DEL1337I DEL1338I DEL1339I DEL1340I DEL1341I DEL1342I DEL1343I DEL1344I DEL1345I DEL1346I DEL1347I DEL1348I DEL1349I DEL1350I DEL1351I DEL1352I DEL1353I DEL1354I DEL1355I DEL1356I DEL1357I DEL1358I DEL1359I DEL1360I DEL1361I DEL1362I DEL1363I DEL1364I DEL1365I DEL1366I DEL1367I DEL1368I DEL1369I DEL1370I DEL1371I DEL1372I DEL1373I DEL1374I DEL1375I DEL1376I DEL1377I DEL1378I DEL1379I DEL1380I DEL1381I DEL1382I DEL1383I DEL1384I DEL1385I DEL1386I DEL1387I DEL1388I DEL1389I DEL1390I DEL1391I DEL1392I DEL1393I DEL1394I DEL1395I DEL1396I DEL1397I DEL1398I DEL1399I DEL1400I DEL1401I DEL1402I DEL1403I DEL1404I DEL1405I DEL1406I DEL1407I DEL1408I DEL1409I DEL1410I DEL1411I DEL1412I DEL1413I DEL1414I DEL1415I DEL1416I DEL1417I DEL1418I DEL1419I DEL1420I DEL1421I DEL1422I DEL1423I DEL1424I DEL1425I DEL1426I DEL1427I DEL1428I DEL1429I DEL1430I DEL1431I DEL1432I DEL1433I DEL1434I DEL1435I DEL1436I DEL1437I DEL1438I DEL1439I DEL1440I DEL1441I DEL1442I DEL1443I DEL1444I DEL1445I DEL1446I DEL1447I DEL1448I DEL1449I DEL1450I DEL1451I DEL1452I DEL1453I DEL1454I DEL1455I DEL1456I DEL1457I DEL1458I DEL1459I DEL1460I DEL1461I DEL1462I DEL1463I DEL1464I DEL1465I DEL1466I DEL1467I DEL1468I DEL1469I DEL1470I DEL1471I DEL1472I DEL1473I DEL1474I DEL1475I DEL1476I DEL1477I DEL1478I DEL1479I DEL1480I DEL1481I DEL1482I DEL1483I DEL1484I DEL1485I DEL1486I DEL1487I DEL1488I DEL1489I DEL1490I DEL1491I DEL1492I DEL1493I DEL1494I DEL1495I DEL1496I DEL1497I DEL1498I DEL1499I DEL1500I DEL1501I DEL1502I DEL1503I DEL1504I DEL1505I DEL1506I DEL1507I DEL1508I DEL1509I DEL1510I DEL1511I DEL1512I DEL1513I DEL1514I DEL1515I DEL1516I DEL1517I DEL1518I DEL1519I DEL1520I DEL1521I DEL1522I DEL1523I DEL1524I DEL1525I DEL1526I DEL1527I DEL1528I DEL1529I DEL1530I DEL1531I DEL1532I DEL1533I DEL1534I DEL1535I DEL1536I DEL1537I DEL1538I DEL1539I DEL1540I DEL1541I DEL1542I DEL1543I DEL1544I DEL1545I DEL1546I DEL1547I DEL1548I DEL1549I DEL1550I DEL1551I DEL1552I DEL1553I DEL1554I DEL1555I DEL1556I DEL1557I DEL1558I DEL1559I DEL1560I DEL1561I DEL1562I DEL1563I DEL1564I DEL1565I DEL1566I DEL1567I DEL1568I DEL1569I DEL1570I DEL1571I DEL1572I DEL1573I DEL1574I DEL1575I DEL1576I DEL1577I DEL1578I DEL1579I DEL1580I DEL1581I DEL1582I DEL1583I DEL1584I DEL1585I DEL1586I DEL1587I DEL1588I DEL1589I DEL1590I DEL1591I DEL1592I DEL1593I DEL1594I DEL1595I DEL1596I DEL1597I DEL1598I DEL1599I DEL1600I DEL1601I DEL1602I DEL1603I DEL1604I DEL1605I DEL1606I DEL1607I DEL1608I DEL1609I DEL1610I DEL1611I DEL1612I DEL1613I DEL1614I DEL1615I DEL1616I DEL1617I DEL1618I DEL1619I DEL1620I DEL1621I DEL1622I DEL1623I DEL1624I DEL1625I DEL1626I DEL1627I DEL1628I DEL1629I DEL1630I DEL1631I DEL1632I DEL1633I DEL1634I DEL1635I DEL1636I DEL1637I DEL1638I DEL1639I DEL1640I DEL1641I DEL1642I DEL1643I DEL1644I DEL1645I DEL1646I DEL1647I DEL1648I DEL1649I DEL1650I DEL1651I DEL1652I DEL1653I DEL1654I DEL1655I DEL1656I DEL1657I DEL1658I DEL1659I DEL1660I DEL1661I DEL1662I DEL1663I DEL1664I DEL1665I DEL1666I DEL1667I DEL1668I DEL1669I DEL1670I DEL1671I DEL1672I DEL1673I DEL1674I DEL1675I DEL1676I DEL1677I DEL1678I DEL1679I DEL1680I DEL1681I DEL1682I DEL1683I DEL1684I DEL1685I DEL1686I DEL1687I DEL1688I DEL1689I DEL1690I DEL1691I DEL1692I DEL1693I DEL1694I DEL1695I DEL1696I DEL1697I DEL1698I DEL1699I DEL1700I DEL1701I DEL1702I DEL1703I DEL1704I DEL1705I DEL1706I DEL1707I DEL1708I DEL1709I DEL1710I DEL1711I DEL1712I DEL1713I DEL1714I DEL1715I DEL1716I DEL1717I DEL1718I DEL1719I DEL1720I DEL1721I DEL1722I DEL1723I DEL1724I DEL1725I DEL1726I DEL1727I DEL1728I DEL1729I DEL1730I DEL1731I DEL1732I DEL1733I DEL1734I DEL1735I DEL1736I DEL1737I DEL1738I DEL1739I DEL1740I DEL1741I DEL1742I DEL1743I DEL1744I DEL1745I DEL1746I DEL1747I DEL1748I DEL1749I DEL1750I DEL1751I DEL1752I DEL1753I DEL1754I DEL1755I DEL1756I DEL1757I DEL1758I DEL1759I DEL1760I DEL1761I DEL1762I DEL1763I DEL1764I DEL1765I DEL1766I DEL1767I DEL1768I DEL1769I DEL1770I DEL1771I DEL1772I DEL1773I DEL1774I DEL1775I DEL1776I DEL1777I DEL1778I DEL1779I DEL1780I DEL1781I DEL1782I DEL1783I DEL1784I DEL1785I DEL1786I DEL1787I DEL1788I DEL1789I DEL1790I DEL1791I DEL1792I DEL1793I DEL1794I DEL1795I DEL1796I DEL1797I DEL1798I DEL1799I DEL1800I DEL1801I DEL1802I DEL1803I DEL1804I DEL1805I DEL1806I DEL1807I DEL1808I DEL1809I DEL1810I DEL1811I DEL1812I DEL1813I DEL1814I DEL1815I DEL1816I DEL1817I DEL1818I DEL1819I DEL1820I DEL1821I DEL1822I DEL1823I DEL1824I DEL1825I DEL1826I DEL1827I DEL1828I DEL1829I DEL1830I DEL1831I DEL1832I DEL1833I DEL1834I DEL1835I DEL1836I DEL1837I DEL1838I DEL1839I DEL1840I DEL1841I DEL1842I DEL1843I DEL1844I DEL1845I DEL1846I DEL1847I DEL1848I DEL1849I DEL1850I DEL1851I DEL1852I DEL1853I DEL1854I DEL1855I DEL1856I DEL1857I DEL1858I DEL1859I DEL1860I DEL1861I DEL1862I DEL1863I DEL1864I DEL1865I DEL1866I DEL1867I DEL1868I DEL1869I DEL1870I DEL1871I DEL1872I DEL1873I DEL1874I DEL1875I DEL1876I DEL1877I DEL1878I DEL1879I DEL1880I DEL1881I DEL1882I DEL1883I DEL1884I DEL1885I DEL1886I DEL1887I DEL1888I DEL1889I DEL1890I DEL1891I DEL1892I DEL1893I DEL1894I DEL1895I DEL1896I DEL1897I DEL1898I DEL1899I DEL1900I DEL1901I DEL1902I DEL1903I DEL1904I DEL1905I DEL1906I DEL1907I DEL1908I DEL1909I DEL1910I DEL1911I DEL1912I DEL1913I DEL1914I DEL1915I DEL1916I DEL1917I DEL1918I DEL1919I DEL1920I DEL1921I DEL1922I DEL1923I DEL1924I DEL1925I DEL1926I DEL1927I DEL1928I DEL1929I DEL1930I DEL1931I DEL1932I DEL1933I DEL1934I DEL1935I DEL1936I DEL1937I DEL1938I DEL1939I DEL1940I DEL1941I DEL1942I DEL1943I DEL1944I DEL1945I DEL1946I DEL1947I DEL1948I DEL1949I DEL1950I DEL1951I DEL1952I DEL1953I DEL1954I DEL1955I DEL1956I DEL1957I DEL1958I DEL1959I DEL1960I DEL1961I DEL1962I DEL1963I DEL1964I DEL1965I DEL1966I DEL1967I DEL1968I DEL1969I DEL1970I DEL1971I DEL1972I DEL1973I DEL1974I DEL1975I DEL1976I DEL1977I DEL1978I DEL1979I DEL1980I DEL1981I DEL1982I DEL1983I DEL1984I DEL1985I DEL1986I DEL1987I DEL1988I DEL1989I DEL1990I DEL1991I DEL1992I DEL1993I DEL1994I DEL1995I DEL1996I DEL1997I DEL1998I DEL1999I DEL2000I DEL2001I DEL2002I DEL2003I DEL2004I DEL2005I DEL2006I DEL2007I DEL2008I DEL2009I DEL2010I DEL2011I DEL2012I DEL2013I DEL2014I DEL2015I DEL2016I DEL2017I DEL2018I DEL2019I DEL2020I DEL2021I DEL2022I DEL2023I DEL2024I DEL2025I DEL2026I DEL2027I DEL2028I DEL2029I DEL2030I DEL2031I DEL2032I DEL2033I DEL2034I DEL2035I DEL2036I DEL2037I DEL2038I DEL2039I DEL2040I DEL2041I DEL2042I DEL2043I DEL2044I DEL2045I DEL2046I DEL2047I DEL2048I DEL2049I DEL2050I DEL2051I DEL2052I DEL2053I DEL2054I DEL2055I DEL2056I DEL2057I DEL2058I DEL2059I DEL2060I DEL2061I DEL2062I DEL2063I DEL2064I DEL2065I DEL2066I DEL2067I DEL2068I DEL2069I DEL2070I DEL2071I DEL2072I DEL2073I DEL2074I DEL2075I DEL2076I DEL2077I DEL2078I DEL2079I DEL2080I DEL2081I DEL2082I DEL2083I DEL2084I DEL2085I DEL2086I DEL2087I DEL2088I DEL2089I DEL2090I DEL2091I DEL2092I DEL2093I DEL2094I DEL2095I DEL2096I DEL2097I DEL2098I DEL2099I DEL2100I DEL2101I DEL2102I DEL2103I DEL2104I DEL2105I DEL2106I DEL2107I DEL2108I DEL2109I DEL2110I DEL2111I DEL2112I DEL2113I DEL2114I DEL2115I DEL2116I DEL2117I DEL2118I DEL2119I DEL2120I DEL2121I DEL2122I DEL2123I DEL2124I DEL2125I DEL2126I DEL2127I DEL2128I DEL2129I DEL2130I DEL2131I DEL2132I DEL2133I DEL2134I DEL2135I DEL2136I DEL2137I DEL2138I DEL2139I DEL2140I DEL2141I DEL2142I DEL2143I DEL2144I DEL2145I DEL2146I DEL2147I DEL2148I DEL2149I DEL2150I DEL2151I DEL2152I DEL2153I DEL2154I DEL2155I DEL2156I DEL2157I DEL2158I DEL2159I DEL2160I DEL2161I DEL2162I DEL2163I DEL2164I DEL2165I DEL2166I DEL2167I DEL2168I DEL2169I DEL2170I DEL2171I DEL2172I DEL2173I DEL2174I DEL2175I DEL2176I DEL2177I DEL2178I DEL2179I DEL2180I DEL2181I DEL2182I DEL2183I DEL2184I DEL2185I DEL2186I DEL2187I DEL2188I DEL2189I DEL2190I DEL2191I DEL2192I DEL2193I DEL2194I DEL2195I DEL2196I DEL2197I DEL2198I DEL2199I DEL2200I DEL2201I DEL2202I DEL2203I DEL2204I DEL2205I DEL2206I DEL2207I DEL2208I DEL2209I DEL2210I DEL2211I DEL2212I DEL2213I DEL2214I DEL2215I DEL2216I DEL2217I DEL2218I DEL2219I DEL2220I DEL2221I DEL2222I DEL2223I DEL2224I DEL2225I DEL2226I DEL2227I DEL2228I DEL2229I DEL2230I DEL2231I DEL2232I DEL2233I DEL2234I DEL2235I DEL2236I DEL2237I DEL2238I DEL2239I DEL2240I DEL2241I DEL2242I DEL2243I DEL2244I DEL2245I DEL2246I DEL2247I DEL2248I DEL2249I DEL2250I DEL2251I DEL2252I DEL2253I DEL2254I DEL2255I DEL2256I DEL2257I DEL2258I DEL2259I DEL2260I DEL2261I DEL2262I DEL2263I DEL2264I DEL2265I DEL2266I DEL2267I DEL2268I DEL2269I DEL2270I DEL2271I DEL2272I DEL2273I DEL2274I DEL2275I DEL2276I DEL2277I DEL2278I DEL2279I DEL2280I DEL2281I DEL2282I DEL2283I DEL2284I DEL2285I DEL2286I DEL2287I DEL2288I DEL2289I DEL2290I DEL2291I DEL2292I DEL2293I DEL2294I DEL2295I DEL2296I DEL2297I DEL2298I DEL2299I DEL2300I DEL2301I DEL2302I DEL2303I DEL2304I DEL2305I DEL2306I DEL2307I DEL2308I DEL2309I DEL2310I DEL2311I DEL2312I DEL2313I DEL2314I DEL2315I DEL2316I DEL2317I DEL2318I DEL2319I DEL2320I DEL2321I DEL2322I DEL2323I DEL2324I DEL2325I DEL2326I DEL2327I DEL2328I DEL2329I DEL2330I DEL2331I DEL2332I DEL2333I DEL2334I DEL2335I DEL2336I DEL2337I DEL2338I DEL2339I DEL2340I DEL2341I DEL2342I DEL2343I DEL2344I DEL2345I DEL2346I DEL2347I DEL2348I DEL2349I DEL2350I DEL2351I DEL2352I DEL2353I DEL2354I DEL2355I DEL2356I DEL2357I DEL2358I DEL2359I DEL2360I DEL2361I DEL2362I DEL2

Update on SARS-CoV-2 Variants Of Concern (VOC)

WHO SARS-CoV-2 Variant Working Definitions, as of 06 July 2021

Variant of Concern

A SARS-CoV-2 variant that meets the definition of a VOI (see below) and, through a comparative assessment, has been demonstrated to be associated with one or more of the following changes at a degree of global public health significance:

- Increase in transmissibility or detrimental change in COVID-19 epidemiology; OR
- Increase in virulence or change in clinical disease presentation; OR
- Decrease in effectiveness of public health and social measures or available diagnostics, vaccines, therapeutics.

Variant of Interest

A SARS-CoV-2 variant:

- with genetic changes that are predicted or known to affect virus characteristics such as transmissibility, disease severity, immune escape, diagnostic or therapeutic escape; AND
- Identified to cause significant community transmission or multiple COVID-19 clusters, in multiple countries with increasing relative prevalence alongside increasing number of cases over time, or other apparent epidemiological impacts to suggest an emerging risk to global public health.

Alerts for Further Monitoring

A SARS-CoV-2 variant with genetic changes that are suspected to affect virus characteristics with some indication that it may pose a future risk, but evidence of phenotypic or epidemiological impact is currently unclear, requiring enhanced monitoring and further assessment pending new evidence.

Summary of phenotypic impacts of Variant of Concern

WHO label	Alpha	Beta	Gamma	Delta
Transmissibility	Increased transmissibility and secondary attack rate ¹²	Increased transmissibility ¹³	Increased transmissibility ¹⁴	Increased transmissibility and secondary attack rate ^{6,15,16}
Disease severity	Increased risk of hospitalization ¹⁷ , possible increased risk of severity and mortality ¹⁸	Not confirmed, possible increased risk of in-hospital mortality ^{19,20}	Not confirmed, possible increased risk of hospitalization ²¹	Not confirmed, possible increased risk of hospitalization ²²
Risk of reinfection	Neutralizing activity retained, ²³ risk of reinfection remains similar ^{24,25}	Reduction in neutralizing activity reported; T cell response elicited by D614G virus remains effective ^{26–29}	Moderate reduction in neutralizing activity reported ^{30,31}	Reduction in neutralizing activity reported ³²
Impacts on diagnostics	Limited impact – S gene target failure (SGTF); no impact on overall result from multiple target RT-PCR, No impact on Ag RDTs observed ³³	No impact on RT-PCR or Ag RDTs observed ³⁴	None reported to date	None reported to date

New evidence has been published on the phenotypic characteristics of the Delta variant. Based on the estimated transmission advantage of the Delta variant, it is expected that Delta will rapidly outcompete other variants and become the dominant circulating lineage over the coming months.

Based on global data submitted to GISAID, the estimated effective reproductive number for the Delta variant is 55% (95%CI 43-68%) higher than the Alpha variant and 97% (95%CI 76-117%) higher relative to non-VOC/VOI.

Summary of vaccine performance against Variants of Concern


The Table below summarises the impact of variants on vaccine efficacy/effectiveness (VE) and quantifies the reduction in VE due to variants compared to VE in non-VOC settings. Of note, reductions in VE do not mean loss of protection, as indicated by the absolute VE estimate. For example, a 10 percent point reduction in VE against symptomatic disease for mRNA vaccines would still mean high vaccine effectiveness of ~85%. In addition, vaccines have shown higher VE against severe disease; thus, small reductions in VE against severe disease due to VOCs may still mean good protection, as is the case for AstraZeneca-Vaxzevria.

Alpha	Beta	Gamma	Delta
Efficacy/effectiveness against disease or infection (full vaccination), see key below table			
Protection retained against all outcomes	Reduced protection against symptomatic disease, but retained against severe disease; limited evidence	Unclear impact; very limited evidence	Protection retained against severe disease; possible reduced protection against symptomatic disease and infection
Severe disease			
<ul style="list-style-type: none"> • ↔ to ↓: Moderna-mRNA-1273 (1), Pfizer BioNTech-Comirnaty (3), Moderna-mRNA-1273/Pfizer BioNTech-Comirnaty (1)^{35,47–49} • ↓: AstraZeneca- Vaxzevria (1)⁴⁹ 	<ul style="list-style-type: none"> • ↔: Janssen Ad26.COV 2.5 (1), Pfizer BioNTech-Comirnaty (1)^{48,50} 	<ul style="list-style-type: none"> • No evidence 	<ul style="list-style-type: none"> • ↔: AstraZeneca- Vaxzevria (1), Pfizer BioNTech-Comirnaty (1)⁴⁹
Symptomatic disease			
<ul style="list-style-type: none"> • ↔: Moderna-mRNA-1273/Pfizer BioNTech-Comirnaty (2), Pfizer BioNTech-Comirnaty (3)^{35,47,51,52} • ↔ to ↓: AstraZeneca-Vaxzevria (3)^{51–53} • ↓: Novavax-Covavax (1)⁵⁴ 	<ul style="list-style-type: none"> • ↔: Janssen-Ad26. COV 2.5 (1)⁵⁰ • ↓↓↓: AstraZeneca-Vaxzevria (1), Novavax-Covavax (1)^{55,56} 	<ul style="list-style-type: none"> • ↔ to ↓: Sinovac-CoronaVac (1)^{36,57} 	<ul style="list-style-type: none"> • ↔ to ↓: Pfizer BioNTech-Comirnaty (3)^{35,51,52} • ↓: Bharat-Covaxin (1)³⁴ • ↓↓: AstraZeneca- Vaxzevria (2)^{51,52}
Infection			
<ul style="list-style-type: none"> • ↔: Pfizer BioNTech-Comirnaty (3)^{52,58} • ↔ to ↓: AstraZeneca-Vaxzevria (2)^{52,53} 	<ul style="list-style-type: none"> • ↓: PfizerBioNTech-Comirnaty (1)⁴⁸ 	<ul style="list-style-type: none"> • No evidence 	<ul style="list-style-type: none"> • ↓: AstraZeneca-Vaxzevria (1), Pfizer BioNTech-Comirnaty (1)⁵²
Neutralization (full vaccination), see key below table			
<ul style="list-style-type: none"> • ↔: Beijing CNBG-BBIBP-CorV (1), Bharat-Covaxin (1), Gamaleya-Sputnik V (1), Novavax-Covavax (1), Sinovac-CoronaVac (2)^{59–63} • ↔ to ↓: Janssen-Ad26.COV 2.5 (2), Moderna- mRNA-1273 (9), Pfizer BioNTech-Comirnaty (26)^{29,37,38,41,63–90} • ↓ to ↓↓: AstraZeneca-Vaxzevria (2)^{53,68} 	<ul style="list-style-type: none"> • ↔ to ↓: Anhui ZL-Recombinant (2), Beijing CNBG-BBIBP-CorV (2)^{59,91,92} • ↓: Bharat-Covaxin (1)⁴² • ↓ to ↓↓: Pfizer BioNTech-Comirnaty (27), Sinovac-CoronaVac (3)^{29,39,41,59,62,64,65,68,70–74,76,77,80–82,86–89,91,93–97} • ↓ to ↓↓↓: Janssen-Ad26.COV 2.5 (3)^{38,90,98} • ↓↓: AstraZeneca-Vaxzevria (3), Gamaleya-Sputnik V (1), Moderna-mRNA-1273 (10)^{37,39,55,61,68,70,76,79,81,85,96,97,99–101} • ↓↓ to ↓↓↓: Janssen-Ad26.COV 2.5 (3)^{38,90,98} • ↓↓↓: Novavax-Covavax (1)⁵⁹ 	<ul style="list-style-type: none"> • ↔: Sinovac-CoronaVac (1)¹⁰² • ↔ to ↓: Pfizer BioNTech-Comirnaty (11)^{43,64,68,70,72,74,77,86,93,103} • ↓: AstraZeneca-Vaxzevria (1), Janssen-Ad26.COV 2.5 (2), Moderna-mRNA-1273 (4)^{37,38,68,70,85,90,103} 	<ul style="list-style-type: none"> • ↔: Janssen-Ad.COV 2.5 (1)³⁸ • ↓: AstraZeneca-Vaxzevria (2), Bharat-Covaxin (1), Moderna-mRNA-1273 (1)^{37,39,42,44} • ↓ to ↓↓: Pfizer BioNTech-Comirnaty (5)^{39,41,43–45}

<https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---6-july-2021>

Update on SARS-CoV-2 Variants Of Concern (VOC)

Countries, territories and areas reporting variants Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1) and Delta (B.1.617.2), as of 06 July 2021



Vaccine Research Updates



According to data collected by Our World in Data, more than 2.97 billion COVID-19 vaccine doses have been administered in 180 countries. As of June 28, the WHO's COVAX program has shipped 89 million doses to 133 eligible countries.

A number of countries/territories are facing a rise in disease activity despite high vaccination coverage, such as **Argentina, Brazil, Colombia, Kuwait, Mongolia, Seychelles, Uruguay, and Saint Kitts and Nevis** (see Figure 2). Other countries are facing a rise in disease activity with the increased dominance of the Delta variant, including **Israel, Portugal, and Australia**.





Figure 2. Bivariate map with COVID-19 incidence rates (represented by the number of cases per 100,000 in the past 14 days) and COVID-19 vaccine coverage (represented by the percent of population vaccinated with one dose of a COVID-19 vaccine) as of June 30. Source: BlueDot COVID-19 Data Suite.



Another research study from the Washington University School of Medicine was recently published in Nature. Results indicate that mRNA vaccines, including those made from BioNTech and Moderna, offers at least 12 weeks of protection against symptomatic COVID-19 after secondary immunization. The study which included 14 individuals who received both doses of the BioNTech vaccine, revealed that the protein sites from vaccines where antibody cells are trained to recognize and combat virus peaked one week after the second vaccination and remained near peak level 12 weeks after the second vaccination. Researchers are continuing to monitor antibody levels in study participants and will provide follow-up results accordingly but these results are promising for a long-lasting immunity produced by mRNA vaccines beyond 12 weeks.

What are the updates for vaccine candidates in Phase 3 or Phase 2/3 trials?:

Company	Vaccine Candidate	Updates
Pfizer/BioNTech 	BNT162	<ul style="list-style-type: none"> In June, a Phase 3 trial was launched to evaluate the safety and efficacy of administering a third booster shot of its vaccine candidate BNT162 combined with Prevnar, Pfizer's pneumococcal vaccine. Roughly 600 individuals aged 65 and older will participate in the study. Results are expected for late November.
Moderna/National Institute of Health 	mRNA-1273	<ul style="list-style-type: none"> The National Institute of Health has begun a Phase 2/3 clinical trial to assess the efficacy of the mRNA-1273 vaccine candidate as a booster shot for those who previously received two doses of the vaccine. The trial will follow 300 persons aged 18+ with an estimated completion date of June 2022.
CureVac 	CvnCoV	<ul style="list-style-type: none"> On June 16, preliminary analysis of Phase 3 trial data revealed that the CvnCoV vaccine candidate had an efficacy of just 47% in preventing COVID-19 of any severity. The represents the lowest value reported from any vaccine manufacturer to date, and is below the World Health Organization's threshold of 50%. The trial involved over 40,000 volunteers across Latin America and Europe. Notably, 57% of identified cases were variants of concern. Monitoring will continue as analysis is completed, with final results expected in July.
Novavax 	NVX-CoV2373	<ul style="list-style-type: none"> On June 16, Novavax announced trial data from the first co-administration study of a SARS-CoV-2 vaccine and an approved influenza vaccine. Results demonstrated that the vaccine efficacy of the NCX-CoV2373 candidate was preserved when administered simultaneously with a flu vaccine, in comparison to alone (87.5% and 89.8%, respectively). The study involved 431 participants based in the UK, half of whom received both shots.
Finlay Vaccine Institute 	Soberana 2	<ul style="list-style-type: none"> On June 10, officials from the Finlay Vaccine Institute announced that clinical trials for its products in children aged 3 to 18 years were approved in Cuba. The trial, named "Sovereign - Pediatrics", will include 350 participants who will receive a heterogenous scheme of two doses of vaccine candidate Soberana 2, followed by one dose of Soberana Plus.
Center for Genetic Engineering and Biotechnology of Cuba 	Abdala	<ul style="list-style-type: none"> On June 21, the Center for Genetic Engineering and Biotechnology of Cuba announced that their vaccine candidate Abdala was 92.28% effective in late stage trials, using a three-dose vaccination schedule. While limited information has been revealed to date, the results would rank the candidate as one of the most effective worldwide. Abdala does not use vector or mRNA technologies, and instead functions as a protein subunit vaccine.
Erciyes University/ Health Institutes of Turkey 	ERUCOV-VAC ("Turkovac")	<ul style="list-style-type: none"> On June 23, the president of Turkey announced the vaccine candidate ERUCOV-VAC had progressed to Phase 3 trials. Few details were provided but the trials will recruit domestic volunteers with an expected completion by November. If successful, it is expected to become the first locally-produced vaccine in Turkey. Authorities have stated Turkovac may be available before the end of 2021.

What does the most research suggest in support of switching to different COVID-19 vaccines for second doses or booster shots of COVID-19 vaccines?

On June 28, the Com-COV study from Oxford University, which compares mixed two-dose schedules of BioNTech and AstraZeneca vaccines, released its positive results published in the Lancet. This was a randomized control trial designed to determine whether a mixed combination of vaccines was at least equivalent or better (i.e., non-inferior) to a homologous (i.e., same vaccine for both doses) regimen. The study included 830 participants randomized across four groups to receive a combination of either AstraZeneca/AstraZeneca, AstraZeneca/BioNTech, BioNTech/BioNTech, or BioNTech/AstraZeneca. Study results showed that **both mixed combinations (AstraZeneca/BioNTech and BioNTech/AstraZeneca) given at a four-week interval induced a significant level of antibodies against the SARS-CoV-2 virus**, which both met the non-inferiority criteria compared to homologous regimen of AstraZeneca/AstraZeneca.

The **highest antibody response** was seen in people receiving **two doses of BioNTech vaccine**, with both mixed combinations producing better responses than two doses of AstraZeneca vaccine. Despite the BioNTech/AstraZeneca regimen not meeting the non-inferiority criteria compared to the homologous BioNTech/BioNTech regimen, the **antibody levels** generated in response to **both mixed combinations were higher than that of a homologous AstraZeneca/AstraZeneca** regimen with proven effectiveness against COVID-19 symptoms and hospitalization. These results support flexibility in mixing the first and second dose with AstraZeneca and BioNTech COVID-19 vaccines.

https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3874014
https://www.nature.com/articles/s41586-021-03738-2_reference.pdf

Other Infectious Disease Outbreaks

Middle Eastern Respiratory Syndrome Coronavirus in Saudi Arabia

Last checked on July 5, 2021




Middle East respiratory syndrome coronavirus (MERS-CoV)

Saudi Arabia— The Ministry of Health has recently reported the ninth case of MERS-CoV of 2021. According to the report, the individual is a 63-year-old man from Almwaih City, Taif who had contact with camels. This is the tenth overall case of the year as the United Arab Emirates reported a case in early February.


So far, 27 countries in the Middle East, Africa and South Asia have reported over 2,500 cases since 2012, leading to nearly 900 known infection related deaths and complications. However, the number of new cases detected and reported through surveillance have dropped to the lowest levels since 2014.

Source: <https://www.ecdc.europa.eu/en/publications-data/communicable-disease-threats-report-27-june-3-july-2021-week-26>

Geographical distribution of confirmed MERS-CoV cases by probable region of infection and exposure, from 1 January to 29 June 2021



Geographical distribution of confirmed MERS-CoV cases by country of infection and year, from April 2012 to 29 June 2021



Measles

Nigeria, Borno State— In a follow-up on the measles outbreak in Borno State, Nigeria, health officials reported an additional 417 suspected cases of Measles last week, bringing the outbreak total to 8,894 this year. Of the total cases, 7,266, or 82 percent were reported in children under five years of age. In addition, four more measles deaths were reported. 99 cumulative associated deaths were reported from Bayo (1), Konduga (2), Gubio (1) Mafa (1), Magumeri (29) and MMC (65) LGAs (CFR 1.1percent). **Source:** <http://outbreaknewstoday.com/nigeria-borno-state-reports-nearly-100-measles-deaths-85384/>

Measles in Nigeria

Last checked on July 3, 2021



Malaria in Nigeria

Last checked on July 4, 2021



Malaria

Nigeria; Gwange Iii, Borno State - Media reports are raising concerns that medical teams on the ground from Médecins Sans Frontières/Doctors Without Borders (MSF) are witnessing a spike in malaria cases and related deaths across children. According to these teams, between January - June 2021, over 10,000 children have required treatment and at least 56% have required hospital admission in Gwange ward, a neighborhood in Maiduguri metropolis, Borno State, Nigeria. These statistics do not include affected adults, making it challenging to assess the true extent of the outbreak and compare trends. Gwange ward is the most populated area of Borno state's capital and has one of the highest numbers of Internally Displaced Persons. MSF has indicated that Gwange Paediatric Hospital has an 80-bed capacity during off-peak malaria seasons but has expanded to 200 in response to the ongoing outbreak and further support the community. Of note, last year, Borno state witnessed a spike in malaria cases and related deaths that occurred outside of the typical peak season (usually between August to mid-October), during which MSF supported the population along with local health officials. BlueDot is closely monitoring this event and will provide further information as it becomes available.

Source: <https://sundiatapost.com/medical-ngo-treats-10717-borno-children-with-malaria-in-6-months-official/>

Malaria

Kenya - Media reports are raising concerns on a significant upward trends of cases of malaria and related deaths in Kenya. Although the numbers provided by these reports may be an under-representation of the true extent of the ongoing trends, health officials are also warning that the most affected have been children below 12-years-old. There are also concerns that antimalarial drugs and kit tests could become shortly unavailable due to the high demand amidst the COVID-19 pandemic and already stretched resources. In addition, media reports have highlighted that the areas hardest hit include Nyando, Nyakach, Seme, and Kisumu East sub-counties within Nandi District, and also the Bungoma District. There is a lack of official reports, but healthcare workers have estimated that there are over 50 daily confirmed cases, and that roughly 40,000 total cases were reported only in May in each Nandi and Bungoma Districts across public hospitals. In Kenya, there are an estimated 3.5 million malaria cases and 10,700 associated deaths each year. According to the World Health Organization, malaria causes more than 400,000 deaths every year worldwide with 229 million cases reported in 2019 alone. BlueDot is closely monitoring this event and will provide further information as it becomes available.

Malaria in Kenya

























































































































Last checked on July 2, 2021



Source: <https://www.standardmedia.co.ke/health/article/2001417230/western-and-rift-valley-regions-record-upsurge-in-malaria-cases>

Summary of information on the individual national Corona restrictions

The icons are linked to the respective information. Please click on the icons for information.

NATO Member State		Health information	Vaccination news	Governmental information	NATO Member State		Health information	Vaccination news	Governmental information
	Albania					Latvia			
	Belgium					Lithuania			
	Bulgaria					Luxembourg			
	Canada					Montenegro			
	Croatia					Netherland			
	Czech Republic					North Macedonia			
	Denmark					Norway			
	Estonia					Poland			
	France					Portugal			
	Germany					Rumania			
	Great Britain					Slovakia			
	Greece					Slovenia			
	Hungary					Spain			
	Italy					Turkey			
	Iceland					USA			

Travel Recommendations and other Useful Links

Travel Recommendations

Many countries have halted some or all international travel since the onset of the COVID-19 pandemic but now have re-open travel some already closed public-travel again. This document outlines key considerations for national health authorities when considering or implementing the gradual return to international travel operations.

The decision-making process should be multisectoral and ensure coordination of the measures implemented by national and international transport authorities and other relevant sectors and be aligned with the overall national strategies for adjusting public health and social measures.

Travel has been shown to facilitate the spread of COVID-19 from affected to unaffected areas. Travel and trade restrictions during a public health event of international concern (PHEIC) are regulated under the International Health Regulations (IHR), part III.

The majority of measures taken by WHO Member States relate to the denial of entry of passengers from countries experiencing outbreaks, followed by flight suspensions, visa restrictions, border closures, and quarantine measures. Currently there are exceptions foreseen for travellers with an essential function or need.

Information on COVID-19 testing and quarantine of air travellers in the EU and the US you can find following the link:

- <https://www.ecdc.europa.eu/en/publications-data/guidelines-covid-19-testing-and-quarantine-air-travellers>
- <https://www.cdc.gov/coronavirus/2019-ncov/travelers/testing-air-travel.html>

More information about traveling worldwide:

- National regulation regarding travel restrictions, flight operation and screening for single countries you will find [here](#) (US) and [here](#) (EU).
- Official IATA travel restrictions. You will find [here](#).

More information about traveling in the EU

- by the **European Commission** you will find here:

<https://www.consilium.europa.eu/en/policies/coronavirus/covid-19-travel-and-transport/>

- The **ECDC** publishes a map of EU Member States, broken down by regions, which show the risk levels across the regions in Europe using a traffic light system. Find it [here](#).

As a general rule, information on new measures will be published 24 hours before they come into effect.

All information should also be made available on [Re-open EU](#), which should contain a cross-reference to the map published regularly by the European Centre for Disease Prevention and Control.

Useful links

ECDC:

- [All info about the COVID-19 pandemic](#); (situation updates, latest news and reports, risk assessments etc.)
- [COVID-19 Vaccine tracker](#)
- [SARS-CoV-2 variants dashboard](#) for EU
- [Latest Risk assessment on COVID-19](#), 15 Feb 2021
- All “guidance’s and technical reports” can be found under “All COVID-19 outputs” on this page [here](#)

WHO:

- Epi-WIN [webinars and updates](#)
- Status of “[COVID-19 Vaccines within WHO](#) EUL/PQ evaluation process” and the “Draft landscape and tracker of [COVID-19 candidate vaccines](#)”
- Weekly [Epidemiological and operational updates](#)
- COVID-19 new variants: [Knowledge gaps and research](#)
- COVID-19 [Dashboard](#)
- [Vaccines explained](#)
- Tracking [SARS-CoV-2 variants](#)
- Science in 5: [WHO’s series on science and COVID-19](#)
- [Quick links](#)

CDC:


- COVID [Data Tracker](#) and [weekly review](#)
- [What’s new and Updated](#)
- [Guidance for COVID-19](#)

References:

- European Centre for Disease Prevention and Control www.ecdc.europa.eu
- World Health Organization WHO; www.who.int
- Centres for Disease Control and Prevention CDC; www.cdc.gov
- European Commission; https://ec.europa.eu/info/live-work-travel-eu/health/coronavirus-response/travel-and-transportation-during-coronavirus-pandemic_en
- Our World in Data; <https://ourworldindata.org/coronavirus>
- Morgenpost; <https://interaktiv.morgenpost.de/corona-virus-karte-infektionen-deutschland-weltweit/>
- BlueDot; <https://bluedot.global/>

Upcoming Events FHPB

We are happy to announce the;
Force Health Protection Event:
COVID-19; A retrospective look at a turbulent time



When: 3rd to 4th November 2021
Location: virtual event via Microsoft Office
Teams platform
Registration: open 3rd May 2021
Call for papers: 3rd May to 25th June 2021
Link: [Registration/Submission page](#)

